Hologic [HOLX] vs ResMed [RMD] Detailed Stock Comparison
Hologic
NASDAQ
Loading...
ResMed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Hologic wins in 7 metrics, ResMed wins in 12 metrics, with 0 ties. ResMed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Hologic | ResMed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 28.24 | 29.85 | Hologic |
| Price-to-Book Ratio | 3.12 | 6.97 | Hologic |
| Debt-to-Equity Ratio | 52.09 | 14.27 | ResMed |
| PEG Ratio | 14.42 | 27.59 | Hologic |
| EV/EBITDA | 12.64 | 21.86 | Hologic |
| Profit Margin (TTM) | 13.79% | 27.22% | ResMed |
| Operating Margin (TTM) | 25.48% | 33.87% | ResMed |
| EBITDA Margin (TTM) | 25.48% | 33.87% | ResMed |
| Return on Equity | 11.38% | 25.86% | ResMed |
| Return on Assets (TTM) | 6.69% | 14.02% | ResMed |
| Free Cash Flow (TTM) | $1.15B | $1.29B | ResMed |
| Dividend Yield | N/A | 0.63% | N/A |
| 1-Year Return | -18.63% | 31.08% | ResMed |
| Price-to-Sales Ratio (TTM) | 3.75 | 8.09 | Hologic |
| Enterprise Value | $15.78B | $41.23B | ResMed |
| EV/Revenue Ratio | 3.91 | 8.01 | Hologic |
| Gross Profit Margin (TTM) | 56.32% | 59.33% | ResMed |
| Revenue per Share (TTM) | $18 | $35 | ResMed |
| Earnings per Share (Diluted) | $2.41 | $9.51 | ResMed |
| Beta (Stock Volatility) | 0.49 | 0.77 | Hologic |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Hologic vs ResMed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hologic | 0.19% | 1.34% | 4.87% | 21.15% | 4.32% | -5.13% |
| ResMed | 1.33% | 1.68% | 10.64% | 16.79% | 19.01% | 24.26% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hologic | -18.63% | -6.75% | 1.87% | 60.33% | 361.11% | 493.89% |
| ResMed | 31.08% | 18.30% | 60.60% | 408.33% | 804.72% | 1,617.48% |
Performance & Financial Health Analysis: Hologic vs ResMed
| Metric | HOLX | RMD |
|---|---|---|
| Market Information | ||
| Market Cap | $15.14B | $41.63B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,889,880 | 1,341,930 |
| 90 Day Avg. Volume | 1,864,063 | 1,032,503 |
| Last Close | $68.06 | $283.90 |
| 52 Week Range | $51.90 - $84.67 | $199.92 - $293.08 |
| % from 52W High | -19.62% | -3.13% |
| All-Time High | $87.88 (May 01, 2023) | $301.34 (Sep 06, 2021) |
| % from All-Time High | -22.55% | -5.79% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.10% |
| Quarterly Earnings Growth | 0.00% | 0.30% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.27% |
| Operating Margin (TTM) | 0.25% | 0.34% |
| Return on Equity (TTM) | 0.11% | 0.26% |
| Debt to Equity (MRQ) | 52.09 | 14.27 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.79 | $40.74 |
| Cash per Share (MRQ) | $8.47 | $8.26 |
| Operating Cash Flow (TTM) | $1.07B | $1.75B |
| Levered Free Cash Flow (TTM) | $760.11M | $1.21B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.63% |
| Last 12-Month Dividend | N/A | $1.59 |
Valuation & Enterprise Metrics Analysis: Hologic vs ResMed
| Metric | HOLX | RMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 28.24 | 29.85 |
| Forward P/E | 14.42 | 27.59 |
| PEG Ratio | 14.42 | 27.59 |
| Price to Sales (TTM) | 3.75 | 8.09 |
| Price to Book (MRQ) | 3.12 | 6.97 |
| Market Capitalization | ||
| Market Capitalization | $15.14B | $41.63B |
| Enterprise Value | $15.78B | $41.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.91 | 8.01 |
| Enterprise to EBITDA | 12.64 | 21.86 |
| Risk & Other Metrics | ||
| Beta | 0.49 | 0.77 |
| Book Value per Share (MRQ) | $21.79 | $40.74 |
Financial Statements Comparison: Hologic vs ResMed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HOLX | RMD |
|---|---|---|
| Revenue/Sales | $1.01B | $1.29B |
| Cost of Goods Sold | $628.00M | $525.33M |
| Gross Profit | $377.30M | $766.41M |
| Research & Development | $61.50M | $83.94M |
| Operating Income (EBIT) | $37.90M | $426.27M |
| EBITDA | $121.70M | $478.18M |
| Pre-Tax Income | $-28.50M | $417.69M |
| Income Tax | $-11.10M | $52.65M |
| Net Income (Profit) | $-17.40M | $365.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HOLX | RMD |
|---|---|---|
| Cash & Equivalents | $1.43B | $932.71M |
| Total Current Assets | $3.21B | $3.21B |
| Total Current Liabilities | $989.70M | $940.52M |
| Long-Term Debt | $2.47B | $801.12M |
| Total Shareholders Equity | $4.62B | $5.55B |
| Retained Earnings | $3.03B | $5.78B |
| Property, Plant & Equipment | $939.80M | $1.39B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HOLX | RMD |
|---|---|---|
| Operating Cash Flow | $28.40M | $430.90M |
| Capital Expenditures | $-24.70M | $-20.80M |
| Free Cash Flow | $129.20M | $554.87M |
| Debt Repayment | $-10.20M | $0 |
| Common Stock Repurchase | $-200.00M | $-75.03M |
Short Interest & Institutional Ownership Analysis
| Metric | HOLX | RMD |
|---|---|---|
| Shares Short | 5.15M | 9.38M |
| Short Ratio | 2.16 | 11.59 |
| Short % of Float | 0.03% | 0.07% |
| Average Daily Volume (10 Day) | 1,889,880 | 1,341,930 |
| Average Daily Volume (90 Day) | 1,864,063 | 1,032,503 |
| Shares Outstanding | 231.73M | 146.90M |
| Float Shares | 220.31M | 145.55M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.03% | 0.65% |
Dividend Analysis & Yield Comparison: Hologic vs ResMed
| Metric | HOLX | RMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.59 |
| Last 12-Month Dividend Yield | N/A | 0.63% |
| 3-Year Avg Annual Dividend | N/A | $1.60 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | $4.79 |
| Ex-Dividend Date | N/A | Feb 13, 2025 |